Spruce Power Holdingの空売り状況は、投資家がSpruce Power Holdingの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Spruce Power Holding (NYSE:SPRU) 株価情報, 空売り情報

Spruce Power Holding

Spruce Power Holding Corp is an owner and operator of distributed solar energy assets across the United States (the U.S.), offering subscription-based services to home solar assets and customer contracts, making renewable energy more accessible to everyone. The Company's customers are homeowners and the Company's core solar service offerings generate revenues through, the sale of electricity generated by its home solar energy systems to homeowners, third-party contracts to sell solar renewable energy credits (SRECs) generated by the solar energy systems for fixed prices and the servicing of those agreements for other institutional owners of home solar energy systems.

Spruce Power Holding Corporation Class A Common Stock

Spruce Power Holding Corp

Spruce Biosciences Inc

UBS analyst Dennis Geiger maintains Shake Shack (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHAK#NYSE">SHAK</a>) with a Neutral and lowers the price target from $140 to $100.

News

Price Target

Analyst Ratings

SHAK

UBS Maintains Neutral on Shake Shack, Lowers Price Target to $100

Ratings for Alkermes (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALKS#NASDAQ">ALKS</a>) were provided by 6 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Alkermes and provided 12-month price targets. The average target is $40.5, accompanied by a high estimate of $52.00 and a low estimate of $32.00. This upward trend is apparent, with the current average reflecting a 5.19% increase from the previous average price target of $38.50.
<img src="https://www.benzinga.com/files/images/story/2025/1745877632_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Alkermes. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Ashwani Verma &#x7C;UBS &#x7C;Lowers &#x7C;Neutral &#x7C; $33.00&#x7C;$38.00 &#x7C; 
&#x7C;David Hoang &#x7C;Deutsche Bank &#x7C;Raises &#x7C;Buy &#x7C; $52.00&#x7C;$40.00 &#x7C; 
&#x7C;Leonid Timashev &#x7C;RBC Capital &#x7C;Announces &#x7C;Sector Perform &#x7C; $40.00&#x7C;- &#x7C; 
&#x7C;Chris Shibutani &#x7C;Goldman Sachs &#x7C;Raises &#x7C;Buy &#x7C; $32.00&#x7C;$30.00 &#x7C; 
&#x7C;Douglas Tsao &#x7C;HC Wainwright &amp; Co. &#x7C;Maintains &#x7C;Neutral &#x7C; $46.00&#x7C;$46.00 &#x7C; 
&#x7C;David Hoang &#x7C;Deutsche Bank &#x7C;Announces &#x7C;Buy &#x7C; $40.00&#x7C;- &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Alkermes. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Alkermes compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Alkermes's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Alkermes's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ALKS/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Alkermes analyst ratings.</a>
<h2>Delving into Alkermes's Background</h2>
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
<h3>Alkermes: A Financial Overview</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Alkermes displayed positive results in 3M. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 13.91%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 34.07%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Alkermes's ROE stands out, surpassing industry averages. With an impressive ROE of 10.63%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Alkermes's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 6.96%, the company showcases efficient use of assets and strong financial health.
Debt Management: Alkermes's debt-to-equity ratio is below the industry average at 0.05, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: Simplified</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALKS

Beyond The Numbers: 6 Analysts Discuss Alkermes Stock

Chubb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CB#NYSE">CB</a>) has outperformed the market over the past 15 years by 1.13% on an annualized basis producing an average annual return of 11.98%. Currently, Chubb has a market capitalization of $112.68 billion. 
Buying $1000 In CB: If an investor had bought $1000 of CB stock 15 years ago, it would be worth $5,348.37 today based on a price of $281.18 for CB at the time of writing.
<h3>Chubb's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745877618_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

$1000 Invested In This Stock 15 Years Ago Would Be Worth This Much Today

During the last three months, 4 analysts shared their evaluations of SLR Inv (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLRC#NASDAQ">SLRC</a>), revealing diverse outlooks from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for SLR Inv, revealing an average target of $15.31, a high estimate of $17.25, and a low estimate of $12.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 1.23%. 
<img src="https://www.benzinga.com/files/images/story/2025/1745877619_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive SLR Inv. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;-----------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Finian O'Shea &#x7C;Wells Fargo &#x7C;Lowers &#x7C;Underweight &#x7C; $12.00&#x7C;$13.00 &#x7C; 
&#x7C;Melissa Wedel &#x7C;JP Morgan &#x7C;Lowers &#x7C;Underweight &#x7C; $15.00&#x7C;$16.50 &#x7C; 
&#x7C;Casey Alexander &#x7C;Compass Point &#x7C;Raises &#x7C;Neutral &#x7C; $17.25&#x7C;$16.50 &#x7C; 
&#x7C;Ryan Lynch &#x7C;Keefe, Bruyette &amp; Woods&#x7C;Raises &#x7C;Market Perform &#x7C; $17.00&#x7C;$16.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to SLR Inv. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of SLR Inv compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for SLR Inv's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into SLR Inv's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/SLRC/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on SLR Inv analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Get to Know SLR Inv Better</h2>
SLR Investment Corp is a closed-end externally managed, non-diversified management investment company that has elected to be treated as a business development company. It provides U.S. middle market businesses and intermediaries with bespoke debt financing solutions to fund working capital, acquisition, refinancing and growth capital requirements. It invests majorly in leveraged middle-market companies in the form of senior secured loans, financing leases and to a lesser extent, unsecured loans and equity securities.
<h3>Financial Insights: SLR Inv</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Revenue Growth: SLR Inv's revenue growth over a period of 3M has faced challenges. As of 31 December, 2024, the company experienced a revenue decline of approximately -5.69%. This indicates a decrease in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Financials sector.
Net Margin: SLR Inv's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 92.15%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): SLR Inv's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 2.28%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): SLR Inv's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 0.92%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 1.04.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

SLRC

The Analyst Verdict: SLR Inv In The Eyes Of 4 Experts

In the current market session, Texas Roadhouse Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXRH#NASDAQ">TXRH</a>) share price is at $166.66, after a 3.11% increase. Moreover, over the past month, the stock fell by 1.34%, but in the past year, went up by 3.66%. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2025/1745877619_0_0.png" alt="Past Year Chart" />

<h3>How Does Texas Roadhouse P/E Compare to Other Companies?</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Compared to the aggregate P/E ratio of the 90.23 in the Hotels, Restaurants &amp; Leisure industry, Texas Roadhouse Inc. has a lower P/E ratio of 24.98. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1745877619_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

Markets

TXRH

Price Over Earnings Overview: Texas Roadhouse

UBS analyst Lloyd Walmsley maintains Tripadvisor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIP#NASDAQ">TRIP</a>) with a Neutral and lowers the price target from $18 to $15.

TRIP

UBS Maintains Neutral on Tripadvisor, Lowers Price Target to $15

Farmers &amp; Merchants (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FMAO#NASDAQ">FMAO</a>) reported quarterly earnings of $0.51 per share which beat the analyst consensus estimate of $0.42 by 21.43 percent. This is a 30.77 percent increase over earnings of $0.39 per share from the same period last year.

Earnings

Earnings Beats

FMAO

Farmers & Merchants Q1 EPS $0.51 Beats $0.42 Estimate

Warren Buffett is considered a hero, mentor<a href="https://www.benzinga.com/general/education/24/08/40652464/warren-buffett-celebrates-94th-birthday-with-1-trillion-market-cap-milestone-a-look-back-at-hig"> and investing legend </a>to many people over the years. An autograph from the legendary investor is a coveted keepsake for many and some are up for sale soon.
What Happened: Continuing <a href="https://www.benzinga.com/25/04/44877870/warren-buffett-the-best-advice-giver-says-melinda-gates-heres-wisdom-she-uses-in-philanthropy">his philanthropic work</a>, Buffett is donating proceeds from a book to a homeless shelter in his hometown of Omaha, Nebraska.
The Stephen Center is receiving proceeds from "60 Years of Berkshire Hathaway," a book that celebrates the 60th anniversary of Berkshire Hathaway Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>)(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>), the conglomerate that Buffett famously runs.
The book includes photos, quotes and stories from Buffett and the late Berkshire vice chairman Charlie Munger, according to Observer.
Buffett previously highlighted the Stephen Center in his annual letter to shareholders this year. The nonprofit saw a boost in phone calls, website visitors and social media followers after Buffett's mention.
"Let's face it: this kind of opportunity, particularly from this kind of person, doesn't happen often," Stephen Center CEO Chris Knauf told Observer.
The nonprofit helps provide emergency shelter services, addiction recovery and affordable housing units, according to the report. You may not be a billionaire like Warren Buffett, but you can uncover hidden gems in the stock market using our proprietary data and pattern recognition — <a href="https://www.benzinga.com/trading-ideas/25/04/45029510/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet-62">check out five stocks flying under the radar that deserve your attention.</a>
Book Sales and Autographs: According to the report, around 5,000 copies of the book are available to purchase at the annual Berkshire Hathaway shareholder meeting happening on May 2 and May 3.
There are 18 copies of the book signed by Buffett and former Berkshire employee and the book's curator Carrie Sova.
The autographed copies of the book are being offered exclusively to shareholders who donate $5,000 or more to the Stephen Center.
Buffett is matching all donations made by shareholders to the Stephen Center dollar-for-dollar.
Earlier this month, the first eight signed copies of the book were sold via auction on the nonprofit's website. Each of the copies sold for more than $5,000, with bids of $2,000 to $100,000. The auction of the first eight books raised $630,000 for the shelter when counting bids and Buffett's matched donations.
The remaining 10 signed copies of the book will be auctioned at the Stephen Center's booth at the Berkshire Hathaway shareholder meeting. Given the fact that there will be thousands of Buffett fans in attendance, the books could go for a higher amount than the first eight copies sold.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/management/25/02/43475330/warren-buffetts-1962-signed-stock-certificate-sells-at-auction-heres-what-it-fetched">Warren Buffett&#8217;s 1962 Signed Stock Certificate Sells At Auction: Here&#8217;s What It Fetched</a></li>
</ul>
Photo: Photo Agency / Shutterstock

Entertainment

Media

Warren Buffett Autographed Books To Help Charity: Here's How You Can Get Legendary Investor's Signature

UBS analyst Manav Gupta maintains Valero Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VLO#NYSE">VLO</a>) with a Buy and lowers the price target from $160 to $150.

UBS Maintains Buy on Valero Energy, Lowers Price Target to $150

UBS analyst Dennis Geiger maintains Wendy's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WEN#NASDAQ">WEN</a>) with a Neutral and lowers the price target from $16 to $14.

UBS Maintains Neutral on Wendy's, Lowers Price Target to $14

Waste Management Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WM#NYSE">WM</a>) reported mixed first-quarter financial results after the bell on Monday, and shares are moving lower. Here&#8217;s a rundown <a href="https://www.benzinga.com/pressreleases/25/04/b45054510/wm-announces-first-quarter-2025-earnings">of the report</a>.
<ul>
<li>Q1 Revenue: $6.02 billion, versus <a href="https://www.benzinga.com/calendars/earnings">estimates</a> of $6.12 billion</li>
</ul>
<ul>
<li>Q1 Adjusted EPS: $1.67, versus estimates of $1.62</li>
</ul>
Total revenue was up 16.7% on a year-over-year basis. Waste Management said it generated $1.21 billion in cash from operations during the quarter, resulting in $475 million in free cash flow, in line with company expectations.
The company ended the first quarter with $216 million in cash and cash equivalents, down from $414 million at the end of the fourth quarter. 
&#8220;These solid&nbsp;first quarter&nbsp;results, as well as the strength and resiliency of our business model, give us confidence we are on pace to achieve our 2025&nbsp;outlook,&#8221; said&nbsp;Jim Fish, president and CEO of Waste Management.
Waste Management <a href="https://www.benzinga.com/pressreleases/25/01/b43324253/wm-announces-fourth-quarter-and-full-year-2024-earnings">previously guided</a> for full-year revenue of $25.5 billion to $25.8 billion. The company also forecasted for full-year free cash flow of approximately $2.68 billion to $2.78 billion when it reported fourth-quarter results.
Waste Management executives will further discuss the quarter on a conference call with investors and analysts at 10 a.m. ET Tuesday morning.
WM Price Action: <a href="http://benzinga.com/quote/WM">Waste Management shares</a> were down 1.78% at $225.01 after-hours at publication Monday, per <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/management/25/04/45053723/nxp-semiconductors-reports-q1-earnings-very-uncertain-operating-environment-tied-to-tariffs-ceo-transition-shares-fall">NXP Semiconductors Reports Q1 Earnings: &#8216;Very Uncertain&#8217; Operating Environment Tied To Tariffs, CEO Transition, Shares Fall</a></li>
</ul>
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/04/45054717/transocean-stock-climbs-after-mixed-q1-results-eps-miss-revenue-beats">Transocean Stock Climbs After Mixed Q1 Results: EPS Miss, Revenue Beats</a></li>
</ul>
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/04/45053893/amkor-technology-shares-climb-after-q1-revenue-beats-q2-revenue-guidance-above-estimates">Amkor Technology Shares Climb After Q1 Revenue Beats, Q2 Revenue Guidance Above Estimates</a></li>
</ul>
Photo: <a href="https://www.shutterstock.com/g/paulmatthew">BCFC</a>/Shutterstock.

After-Hours Center

Movers

Waste Management Stock Dips On Mixed Q1 Results, Company Says It's 'On Pace' To Achieve 2025 Outlook

UBS analyst Dennis Geiger maintains Wingstop (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WING#NASDAQ">WING</a>) with a Neutral and lowers the price target from $300 to $255.

WING

UBS Maintains Neutral on Wingstop, Lowers Price Target to $255

UBS analyst Timothy Arcuri maintains Micron Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) with a Buy and lowers the price target from $130 to $92.

UBS Maintains Buy on Micron Technology, Lowers Price Target to $92

UBS analyst Spiro Dounis maintains Phillips 66 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSX#NYSE">PSX</a>) with a Buy and lowers the price target from $144 to $140.

UBS Maintains Buy on Phillips 66, Lowers Price Target to $140

NOV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOV#NYSE">NOV</a>) sees Q2 sales of $2.171 billion-$2.238 billion vs $2.18 billion analyst estimate.

Guidance

NOV Sees Q2 Sales $2.171B-$2.238B vs $2.18B Est

UBS analyst Thomas Wadewitz maintains Saia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIA#NASDAQ">SAIA</a>) with a Buy and lowers the price target from $422 to $305.

SAIA

UBS Maintains Buy on Saia, Lowers Price Target to $305

National Research (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRC#NASDAQ">NRC</a>) reported quarterly earnings of $0.25 per share. This is a 7.41 percent decrease over earnings of $0.27 per share from the same period last year. The company reported $33.55 million in sales this quarter. This is a 4.99 percent decrease over sales of $35.31 million the same period last year.

National Research Q1 EPS $0.25 Down From $0.27 YoY, Revenue $33.55M Down From $35.31M YoY

NOV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOV#NYSE">NOV</a>) reported quarterly earnings of $0.19 per share which missed the analyst consensus estimate of $0.26 by 26.92 percent. This is a 36.67 percent decrease over earnings of $0.30 per share from the same period last year. The company reported quarterly sales of $2.10 billion which met the analyst consensus estimate. This is a 2.41 percent decrease over sales of $2.15 billion the same period last year.

Earnings Misses

NOV Q1 EPS $0.19 Misses $0.26 Estimate, Sales $2.10B Inline

UBS analyst Dennis Geiger maintains Starbucks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>) with a Neutral and lowers the price target from $105 to $90.

SBUX

UBS Maintains Neutral on Starbucks, Lowers Price Target to $90

Krystal Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRYS#NASDAQ">KRYS</a>) has outperformed the market over the past 5 years by 15.4% on an annualized basis producing an average annual return of 29.66%. Currently, Krystal Biotech has a market capitalization of $4.89 billion. 
Buying $100 In KRYS: If an investor had bought $100 of KRYS stock 5 years ago, it would be worth $359.67 today based on a price of $169.73 for KRYS at the time of writing.
<h3>Krystal Biotech's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745876711_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Comments

Spruce Power Holding

空売り

Spruce Power Holding (NYSE:SPRU) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル